Peter Soparkar - Mar 1, 2023 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: Chief Operating Officer
Signature: Peter Soparkar, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: ADVM
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/3/2023, 04:22 PM
Previous filing: Sep 21, 2022
Next filing: Mar 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADVM	Stock Option (Right to Buy)	Award	$0	+400K		$0.00	400K	Mar 1, 2023	Common Stock	400K	$0.75	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total number of shares subject to the option shall vest and become exercisable on the first anniversary of March 1, 2023 (the "Vesting Commencement Date"), and one-forty-eighth (1/48th) of the total number of shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Content

Twenty-five percent (25%) of the total number of shares subject to the option shall vest and become exercisable on the first anniversary of March 1, 2023 (the "Vesting Commencement Date"), and one-forty-eighth (1/48th) of the total number of shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.